SOAT1 and Alzheimer disease: JAK-STAT pathway inhibitors were also shown to be safe and efficacious for use in AD, and, thus, abrocitinib and upadacitinib have both been approved by the European Commission, Health Canada, and the FDA for use in moderate-to-severe AD [30].